SCHEMBL1799258

SCHEMBL1799258

O=CCCN1c2ccccc2CCc2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.56
SLC6A4 P31645 8/20 0.51
SLC6A2 P23975 4/20 0.51
HRH1 P35367 4/20 0.51
CHRM2 P08172 4/20 0.51
CHRM1 P11229 4/20 0.51
DRD3 P35462 4/20 0.51
DRD2 P14416 3/20 0.51
CHRM3 P20309 3/20 0.51
SLC22A1 O15245 3/20 0.51
ADRA1A P35348 3/20 0.51
CACNA1B Q00975 3/20 0.51
SLC6A3 Q01959 3/20 0.51
KCNH2 Q12809 3/20 0.51
SLC22A2 O15244 2/20 0.51
SLC22A3 O75751 2/20 0.51
CYP2D6 P10635 2/20 0.51
ADRA2B P18089 2/20 0.51
ADRA2C P18825 2/20 0.51
HTR2C P28335 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19852198 0.81 HTR7 (0.59) DRD3DRD2HTR7DRD4HTR1A
SCHEMBL28003954 0.79 ALDH1A1 (0.70) CHRM2CHRM1CHRM3LMNAMAPT
SCHEMBL9404599 0.79 HTR2A (0.61) HTR2ASLC6A4SLC6A2HRH1CHRM2
SCHEMBL4920568 0.78 SLC6A4 (0.65) HTR2ASLC6A4SLC6A2HRH1CHRM2
SCHEMBL13051501 0.78 HTR2A (0.78) HTR2ASLC6A4SLC6A2HRH1CHRM2
SCHEMBL21245399 0.77 SLC6A4 (0.59) HTR2ASLC6A4SLC6A2HRH1CHRM2
SCHEMBL3660183 0.76 ALDH1A1 (0.62) CHRM2CHRM1DRD3DRD2CHRM3
SCHEMBL4431813 0.75 POLB (0.61) CHRM2CHRM1DRD3DRD2CHRM3
SCHEMBL22018905 0.75 HTR2A (0.61) HTR2ASLC6A4SLC6A2HRH1CHRM2
SCHEMBL11222427 0.75 HTR2A (0.61) HTR2ASLC6A4SLC6A2HRH1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951796-B2 9-amino-acridine derivatives and their use for eliminating misfolded proteins KORTH CARSTEN 2011-05-31 US disclosed
US-20090209516-A1 9-AMINO-ACRIDINE DERIVATIVES AND METHOD OF TREATING AUTOIMMUNE DISEASES USING THE SAME KORTH CARSTEN 2009-08-20 US disclosed
US-20090124001-A1 9-AMINO-ACRIDINE DERIVATIVES AND THEIR USE FOR ELIMINATING MISFOLDED PROTEINS HEINRICH-HEINE UNIVERSITÄT DUSSELDORF (DE) 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209516-A1 9-AMINO-ACRIDINE DERIVATIVES AND METHOD OF TREATING AUTOIMMUNE DISEASES USING THE SAME SSB, HSPA5, UACA HTR2A 2033/4885SLC6A4 1748/4885SLC6A2 1866/4885
US-20090124001-A1 9-AMINO-ACRIDINE DERIVATIVES AND THEIR USE FOR ELIMINATING MISFOLDED PROTEINS HSPA5, ERP29, DNAJC10 HTR2A 2234/4885SLC6A4 2239/4885SLC6A2 2302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.